Skip to main content
Premium Trial:

Request an Annual Quote

Kenneth Berlin

Rosetta Genomics President and CEO Kenneth Berlin is resigning from the company effective April 18 to pursue other opportunities. He will assist the company in a smooth transition with ongoing projects, the company said. Berlin joined Rosetta Genomics in November 2009 as president and CEO. Before that, he was worldwide general manager at Veridex, a Johnson & Johnson company. He joined J&J in 1994 and was its corporate counsel for six years, according to Rosetta Genomics' website. From 2001 to 2004, he was vice president of licensing and new business development in the pharmaceutical group at J&J, and from 2004 to 2007, he was worldwide VP of franchise development at Ortho Clinical Diagnostics, also a J&J company. 

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.